HPV16 L2 Antibody (2JGmab#2): sc-65707

HPV16 L2 Antibody (2JGmab#2) is a mouse monoclonal IgG1 antibody that detects HPV16 L2 specifically in HPV-16 by western blotting (WB) and immunofluorescence (IF). HPV16 L2 plays a crucial role in the life cycle of the human papillomavirus, particularly in the assembly and encapsidation of the viral genome. HPV16 L2 is located in the nucleus, where anti-HPV16 L2 antibody (2JGmab#2) shows interaction with the major capsid protein L1, facilitating the initial steps of viral infection. The C-terminal region of HPV16 L2 is essential for binding to L1, which is necessary for the efficient encapsidation of the viral DNA. This interaction ensures the proper assembly of the viral capsid, allowing the virus to effectively infect host cells. Additionally, HPV16 L2′s localization to punctate nuclear regions known as promonocytic leukemia protein oncogenic domains (PODs) highlights its importance in the viral life cycle and potential oncogenic processes. HPV16 L2 monoclonal antibody (2JGmab#2) is an invaluable tool for researchers studying the mechanisms of HPV infection and the development of cervical cancer, providing insights into the interactions between viral proteins and host cellular machinery.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HPV16 L2 Antibody (2JGmab#2) References:

1. Modification of human papillomavirus minor capsid protein L2 by sumoylation.  |  Marusic, MB., et al. 2010. J Virol. 84: 11585-9. PMID: 20739540
2. The high risk HPV16 L2 minor capsid protein has multiple transport signals that mediate its nucleocytoplasmic traffic.  |  Mamoor, S., et al. 2012. Virology. 422: 413-24. PMID: 22154072
3. Topography of the Human Papillomavirus Minor Capsid Protein L2 during Vesicular Trafficking of Infectious Entry.  |  DiGiuseppe, S., et al. 2015. J Virol. 89: 10442-52. PMID: 26246568
4. Host cell transcriptome modification upon exogenous HPV16 L2 protein expression.  |  An, X., et al. 2017. Oncotarget. 8: 90730-90747. PMID: 29207600
5. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.  |  Pouyanfard, S., et al. 2018. J Virol. 92: PMID: 29212932
6. Genetic variability in minor capsid protein (L2 gene) of human papillomavirus type 16 among Indian women.  |  Mane, A., et al. 2022. Med Microbiol Immunol. 211: 153-160. PMID: 35552511
7. Human Papillomavirus Minor Capsid Protein L2 Mediates Intracellular Trafficking into and Passage beyond the Endoplasmic Reticulum.  |  Morante, AV., et al. 2022. Microbiol Spectr. 10: e0150522. PMID: 35608352
8. Crystal Structures of Plk1 Polo-Box Domain Bound to the Human Papillomavirus Minor Capsid Protein L2-Derived Peptide.  |  Jung, S., et al. 2023. J Microbiol. 61: 755-764. PMID: 37684534
9. Bacterial Outer Membrane Vesicles as a Platform for the Development of a Broadly Protective Human Papillomavirus Vaccine Based on the Minor Capsid Protein L2.  |  Tamburini, S., et al. 2023. Vaccines (Basel). 11: PMID: 37896984
10. Advances on two serological assays for human papillomavirus provide insights on the reactivity of antibodies against a cross-neutralization epitope of the minor capsid protein L2.  |  Mariz, FC., et al. 2023. Front Immunol. 14: 1272018. PMID: 38022617

The preferred HPV16 L2 antibody is HPV16 L2 Antibody (2JGmab#5): sc-65709.